A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
A phase 2 trial of Niraparib in ovarian cancer, run by GlaxoSmithKline, now recruiting.
Overview
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study is a phase 2 interventional study registered as NCT04641247 by GlaxoSmithKline, with 37 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-12-28. Interventions recorded: Niraparib.
Setting
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
Phase
Phase 2
Sponsor
GlaxoSmithKline
Registry
Enrolled
37
Similar pages
not linked directly; found by shared links- TrialA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Shares Niraparib, GSK, Ovarian cancer and the tag pipeline.
- TrialA Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
- TrialEfficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
- TrialA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares GSK and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares GSK and the tag pipeline.
- TrialFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Shares GSK and the tag pipeline.
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Shares GSK and the tag pipeline.